For instance, tepotinib and savolitinib were combined with gefitinib in EGFR‐TKI‐refractory EGFR‐mutated NSCLC patients who acquired EGFR‐TKI resistance associated with MET amplification. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.